



AN OVERVIEW: ANTI-ULCER AGENT

Vaishnavi J. Shinde¹, Shankar S. Khandare^{1*}, Pawan S. Hanute¹, Komal S. Pawar¹,
Trupti S. Bocharé

¹Raosaheb Patil Danve College of Pharmacy, Badnapur
Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad MS

Corresponding Author: Vaishnavi J. Shinde, Raosaheb Patil Danve College of Pharmacy, Badnapur Dr. Babasaheb Ambedkar Technological University, Lonere, Raigad MS

ABSTRACT


Anti-ulcer agents are pharmacological compounds used to prevent and treat ulcers of the gastrointestinal tract, particularly those affecting the stomach and duodenum. These agents act through various mechanisms, including suppression of gastric acid secretion, enhancement of mucosal defense, and promotion of healing of the gastric lining. Major classes of anti-ulcer drugs include proton pump inhibitors (PPIs), H₂-receptor antagonists, antacids, and mucosal protective agents. In recent years, increasing attention has been given to herbal and natural products for anti-ulcer therapy due to their potential efficacy and favorable safety profiles. A thorough understanding of the mechanisms of action, therapeutic indications, and adverse effects of anti-ulcer agents is essential for the effective management of peptic ulcer disease and for improving patient outcomes.

KEYWORDS: Anti-Ulcer Agents; Peptic Ulcer Disease; Anti-Ulcer Drugs; Screening Models.

INTRODUCTION

Anti-ulcer agents are pharmacological substances used for the prevention and treatment of ulcers in the gastrointestinal tract, particularly gastric and duodenal ulcers. Peptic ulcer disease (PUD) is one of the most common gastrointestinal disorders encountered in clinical practice. It is characterized by open sores that develop on the inner lining of the stomach or the upper part of the small intestine.

Anti-ulcer drugs are classified based on their mechanisms of action. Proton pump inhibitors (PPIs), such as omeprazole and pantoprazole, suppress gastric acid secretion by inhibiting the proton pump and are considered the most effective therapy. H₂-receptor antagonists, including ranitidine and famotidine, reduce acid secretion by blocking histamine-mediated stimulation. Antacids provide rapid symptomatic relief by neutralizing gastric acid, while mucosal protective agents like sucralfate form a protective barrier over the ulcer site and promote healing.





Anti-ulcer drugs are used in the treatment of gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), reflux esophagitis, Zollinger–Ellison syndrome, and other acid-related gastrointestinal disorders. Despite the effectiveness of modern synthetic drugs, their long-term use is associated with adverse effects such as arrhythmias, gynecomastia, renal impairment, and hematopoietic changes. Therefore, there is increasing interest in herbal and indigenous medicines, which are believed to have fewer side effects and better patient tolerance.

CAUSES OF PEPTIC ULCER

The most common causes of peptic ulcer disease include:


- Infection with *Helicobacter pylori* (*H. pylori*)
- Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen
- Excess gastric acid secretion
- Reduced mucous and bicarbonate secretion
- Smoking and alcohol consumption

- Emotional stress
- Radiation therapy
- Skipping meals and irregular dietary habits
- Steroid therapy (especially without food or antacids)

TYPES OF ULCERS

1. Peptic ulcer
2. Oesophageal ulcer
3. Mouth ulcer
4. Arterial ulcer
5. Diabetic foot ulcer
6. Venous ulcer
7. Genital ulcer

A peptic ulcer is a condition characterized by the formation of open sores on the inner lining of the stomach (gastric ulcer) or the upper part of the small intestine, particularly the duodenum (duodenal ulcer).




It occurs when the normal protective mechanisms of the gastrointestinal mucosa are disrupted, leading to damage by aggressive factors such as gastric acid, pepsin, *Helicobacter pylori* infection, or prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs). Common symptoms include burning or gnawing abdominal pain, bloating, nausea, and in severe cases bleeding, which may present as vomiting blood or black, tarry stools. If left untreated, peptic ulcers can lead to serious complications such as perforation, hemorrhage, and gastric obstruction.

SYMPTOMS OF PEPTIC ULCER

Many patients with peptic ulcers may remain asymptomatic.

When symptoms are present, they include:

- Burning or dull epigastric pain
- Pain worsening between meals or at night
- Postprandial pain in some patients
- Feeling of fullness or bloating
- Belching and heartburn
- Nausea and vomiting

**Complications such as bleeding ulcers may present with**

- Vomiting blood (hematemesis)
- Black or tarry stools (melena)
- Dizziness or fainting

RISK FACTORS

- Cigarette smoking
- Excessive alcohol consumption
- Old age (above 60 years)
- High-dose or prolonged NSAID use
- Severe illness (e.g., patients on ventilators)
- Radiation therapy
- Family history of peptic ulcer
- Untreated psychological stress
- Consumption of spicy foods

NATURAL DRUGS USED IN ANTI-ULCER THERAPY

Several natural remedies have been traditionally used to manage ulcers:

- 1) **Liquorice root** – protects gastric mucosa and promotes healing
- 2) **Aloe vera** – reduces inflammation and soothes gastric lining
- 3) **Cabbage juice** – promotes ulcer healing
- 4) **Honey (Manuka)** – possesses antibacterial and healing properties
- 5) **Slippery elm** – coats and protects the stomach lining
- 6) **Chamomile** – soothes the digestive system
- 7) **Turmeric (Curcumin)** – exhibits anti-inflammatory and antioxidant effects
- 8) **Probiotics** – improve gut health and restore microbial balance

DRUGS USED IN ANTI-ULCER THERAPY**1. Proton Pump Inhibitors (PPIs)**

Examples: Omeprazole, Esomeprazole, Pantoprazole.

Function: Inhibit gastric acid secretion by blocking H⁺/K⁺ ATPase enzyme.

2. H₂-Receptor Antagonists

Examples: Famotidine, Cimetidine.

Function: Block histamine H₂ receptors to reduce acid secretion.

3. Antacids

Examples: Aluminium hydroxide, Magnesium hydroxide, Calcium carbonate

Function: Neutralize gastric acid.

4. Mucosal Protective Agents

Examples: Sucralfate, Misoprostol.

Function: Protect gastric mucosa and promote healing.

5. Antibiotics (for *H. pylori*)

Examples: Amoxicillin, Clarithromycin, Metronidazole.

Function: Eradicate *H. pylori* infection.

TREATMENT OF PEPTIC ULCER**1. Pharmacological Treatment**

- ✓ Proton pump inhibitors
- ✓ H₂-receptor antagonists
- ✓ Antacids
- ✓ Antibiotics for *H. pylori* infection
- ✓ Cytoprotective agents

2. Lifestyle Modifications

- ✓ Avoid spicy foods, caffeine, alcohol, and smoking
- ✓ Eat small, frequent meals
- ✓ Stress management through yoga and meditation
- ✓ Avoid NSAIDs

MEDICINAL PLANTS WITH ANTI-ULCER ACTIVITY

Several medicinal plants used in Indian traditional medicine possess significant anti-ulcer activity. Experimental studies in



animal models have demonstrated dose-dependent gastroprotective effects without notable toxicity. Phytochemical investigations reveal that these plants contain bioactive secondary metabolites such as flavonoids, tannins, and phenolic compounds, which contribute to their antioxidant, anti-inflammatory, and mucosal-protective actions. Although comprehensive clinical evidence is limited, herbal anti-ulcer drugs are increasingly gaining attention due to their therapeutic efficacy, safety, and lower incidence of adverse effects compared to synthetic medications.

MECHANISM OF ACTION OF ANTI-ULCER DRUGS

Anti-ulcer drugs act through different mechanisms to reduce gastric acidity and promote ulcer healing. Proton pump inhibitors (PPIs) irreversibly inhibit the H^+/K^+ ATPase enzyme in gastric parietal cells, leading to prolonged suppression of gastric acid secretion and enhanced mucosal healing. H_2 -receptor antagonists competitively block histamine H_2 receptors on parietal cells, thereby reducing acid secretion and providing symptomatic relief in acid-related disorders.

PATHOPHYSIOLOGY OF PEPTIC ULCER

Peptic ulcer disease develops due to an imbalance between aggressive factors such as gastric acid, pepsin, *Helicobacter pylori* infection, and NSAID use, and protective mechanisms including mucus, bicarbonate secretion, and prostaglandin synthesis. Additional factors such as oxidative stress and the generation of free radicals further contribute to mucosal damage, inflammation, and delayed ulcer healing.

CONTRAINDICATIONS OF ANTI-ULCER DRUGS

The use of anti-ulcer medications may be limited by certain contraindications. Proton pump inhibitors are contraindicated in patients with hypersensitivity and require caution in severe liver disease. H_2 -receptor antagonists should be used carefully in individuals with renal impairment or known hypersensitivity. Antacids are contraindicated in severe renal failure and hypophosphatemia, while misoprostol is strictly contraindicated during pregnancy due to its abortifacient effects. Additionally, caution is required when these drugs are used concurrently with other medications to avoid adverse drug interactions.

RESULTS AND DISCUSSION

The reviewed literature demonstrates that peptic ulcer disease is a multifactorial gastrointestinal disorder resulting from an imbalance between aggressive factors such as gastric acid, pepsin, *Helicobacter pylori* infection, non-steroidal anti-inflammatory drugs (NSAIDs), oxidative stress, and impaired mucosal defense mechanisms including mucus, bicarbonate, and prostaglandin secretion. Experimental and clinical studies confirm that excessive acid secretion and mucosal injury play a central role in ulcerogenesis.

Synthetic anti-ulcer drugs, particularly proton pump inhibitors (PPIs) and H_2 -receptor antagonists, have shown significant efficacy in reducing gastric acid secretion and promoting ulcer healing. PPIs act by irreversibly inhibiting the H^+/K^+ -ATPase

enzyme in gastric parietal cells, leading to prolonged acid suppression and improved healing outcomes. H_2 -receptor antagonists reduce acid secretion through competitive inhibition of histamine H_2 receptors, providing effective symptomatic relief. These pharmacological agents have been widely validated through experimental and clinical studies and remain the mainstay of peptic ulcer management. However, long-term use of synthetic anti-ulcer drugs is associated with several adverse effects and contraindications, such as hepatic and renal impairment, hypersensitivity reactions, electrolyte imbalance, and drug interactions. These limitations have encouraged researchers to explore alternative therapies with improved safety profiles.

Medicinal plants traditionally used in Indian systems of medicine have demonstrated promising anti-ulcer activity in experimental animal models. Studies reveal that plant extracts such as *Aloe vera*, *Ocimum basilicum*, *Centella asiatica*, *Pongamia pinnata*, and *Jasminum grandiflorum* provide dose-dependent gastroprotection without significant toxicity. Phytochemical analyses indicate that flavonoids, tannins, and phenolic compounds contribute to their anti-ulcer effects by enhancing mucosal defense, scavenging free radicals, and reducing inflammation. Despite limited clinical data, these herbal agents offer potential therapeutic benefits due to their efficacy, safety, and lower incidence of side effects.

The reviewed evidence also highlights the crucial role of oxidative stress in ulcer formation, where reactive oxygen species damage gastric mucosa. Both synthetic drugs and plant-based antioxidants help mitigate oxidative injury, thereby facilitating mucosal healing. Eradication of *H. pylori* remains a key therapeutic strategy, with combination therapy involving acid suppressants and antibiotics providing superior clinical outcomes.

CONCLUSION

Peptic ulcer disease remains a significant global health concern influenced by acid secretion, mucosal defense failure, *Helicobacter pylori* infection, NSAID use, and oxidative stress. Anti-ulcer agents such as proton pump inhibitors, H_2 -receptor antagonists, antacids, and mucosal protective agents play a vital role in effective ulcer management by reducing gastric acidity and promoting mucosal healing. While these drugs are highly effective, their long-term use may lead to adverse effects, highlighting the need for safer therapeutic alternatives.

Medicinal plants with anti-ulcer activity have emerged as promising candidates due to their gastroprotective properties, antioxidant potential, and low toxicity. Although most evidence is derived from experimental studies, these herbal agents offer a valuable complementary or alternative approach to conventional therapy. Future research should focus on well-designed clinical trials to validate the efficacy, safety, and standardization of plant-based anti-ulcer drugs. An integrated approach combining pharmacological therapy, herbal medicine, and lifestyle



modification may provide optimal management of peptic ulcer disease.

REFERENCE

1. Black JW, Duncan WAM, Durant CJ, Ganellin CR, Parsons ME. Definition and antagonism of histamine H₂-receptors. *Nature*. 1972;236:385-390.
2. Hammer R, Giachetti A. Muscarinic receptor subtypes: M₁ and M₂. Biochemical and functional characterization. *Life Sciences*. 1982;31:2991-2998.
3. Hirschowitz BI, Hammer R, Giachetti A, Keirns JJ, Levine RR. Subtypes of muscarinic receptors. *Trends in Pharmacological Sciences*. 1984;(Suppl):103.
4. Rosenfeld GC. Pirenzepine (LS 519): A weak inhibitor of acid secretion by isolated rat parietal cells. *European Journal of Pharmacology*. 1982;86:99-101.
5. Kulkarni SK. *Handbook of Experimental Pharmacology*. 3rd ed. New Delhi: Vallabh Prakashan; 1999. p. 128-131.
6. Udaya B, Dipak Das D, Ranajit K, Banerjee. Role of reactive oxygen species in mercaptomethylimidazole-induced gastric acid secretion and stress-induced gastric ulceration. *Current Science*. 1999;55-56.
7. Sivaganam K, Rajsekharan S, Narayanan V, Subramanian S. Biochemical evaluation of the ulcer curative effect of Aloe vera on experimental rats. *Journal of Natural Remedies*. 2003;3(2):161-165.
8. Singh S. Evaluation of gastric anti-ulcer activity of fixed oil of *Ocimum basilicum* Linn. and its possible mechanism of action. *Indian Journal of Experimental Biology*. 1999;37:253-257.
9. Prabha T, Dora BM, Priyambada S, Debnath PK, Goel RK. Evaluation of *Pongamia pinnata* root extract on gastric ulcers and mucosal offensive and defensive factors in rats. *Indian Journal of Experimental Biology*. 2003;41:304-310.
10. Sairam K, Rao CV, Goel RK. Effect of *Centella asiatica* Linn. on physical and chemical factor-induced gastric ulceration and secretion in rats. *Indian Journal of Experimental Biology*. 2001;39(4):1-6.
11. Agurav M, Rimpi A, Shaba P. Study of different experimental models used in peptic ulcer. *International Journal of Recent Advances in Pharmaceutical Research*. 2015;5(2):31-37.
12. Shirisha B, Subash V. Animal models in experimental gastric ulcer screening: A review. *International Research Journal of Pharmacy*. 2012;3(6):57-77.
13. Hojgaard L, Nielsen AM, Rune SJ. Peptic ulcer pathophysiology: Acid, bicarbonate, and mucosal function. *Scandinavian Journal of Gastroenterology*. 1996;31(1):10-15.
14. Garner A, Flemstrom G, Allen A. Gastroduodenal alkaline and mucus secretion. *Scandinavian Journal of Gastroenterology*. 1981;18(Suppl 87):25-41.
15. Isenberg JI, Flemstrom G. Physiology and pathophysiology of gastroduodenal bicarbonate secretion. *Digestive Diseases*. 1991;23:27-33.
16. Graham DY, Rakel RE, Fendrick AM, et al. Recognizing peptic ulcer disease: Keys to clinical and laboratory diagnosis. *Postgraduate Medicine*. 1999;105(3):113-133.
17. Mahajan N, Sanghai D. Evaluation of anti-ulcer potential of leaves of *Jasminum grandiflorum* L. *International Journal of Pharmaceutical Sciences*. 2009;1(9):247-249.
18. Martin JB. Not all *Helicobacter pylori* strains are created equal: Should all be eliminated? *The Lancet*. 1997;349:1020-1022.
19. Fan XG, Kelleher D, Fan XJ, Xia HX, Keeling PW. *Helicobacter pylori* increases proliferation of gastric epithelial cells. *Gut*. 1996;38:19-22.
20. Marshall B, Warren JR. Unidentified curved bacilli in active chronic gastritis. *The Lancet*. 1983;1:1-5.
21. Akram M, et al. Peptic ulcer and *Helicobacter pylori* eradication: A review article. *International Journal of Medical Sciences*. 2010;2:370-375.
22. Szabo S, Vincze A, Sandor Z, Jadus M, Gombos Z, Pedram A, et al. Vascular approach to gastroduodenal ulceration: New studies with endothelins and VEGF. *Digestive Diseases and Sciences*. 1998;43:40-45.
23. Aihara T, Nakamura E, Amagase K, Tomita K, Fujishita T, Furutani K, et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: Past, present, and future. *Pharmacology & Therapeutics*. 2003;98:109-123.
24. Tasman JC. Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. *Scandinavian Journal of Gastroenterology*. 1986;21:1-5.
25. Lindstrom E, Chen D, Norlen P, Andersson K, Hakanson R. Control of gastric acid secretion: The gastrin-ECL cell-parietal cell axis. *Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology*. 2001;128:505-514.